Does Tafamidis Attenuate the Benefits of Vutrisiran in ATTR-CM? | JACC Baran
Episode Description
Does adding a gene silencer to a TTR stabiliser provide additional benefit in transthyretin amyloid cardiomyopathy (ATTR-CM)? Host Mitsuaki Sawano, MD, and co-host Nobuhiro Ikemura, MD, welcome Yasuhiro Hamatani, MD, PhD (Brigham and Women's Hospital, Harvard Medical School) to discuss his JACC study, published simultaneously with ESC 2026, examining vutrisiran efficacy according to baseline tafamidis use in the HELIOS-B trial. Although treatment benefits were directionally consistent regardless of tafamidis use, effect estimates were numerically attenuated among patients receiving tafamidis, without significant interactions for major clinical outcomes. We explore the implications for mortality, cardiovascular events, exercise capacity, and quality of life, alongside emerging evidence from CARDIO-TTRansform and a subsequent meta-analysis. Can combination therapy deliver meaningful incremental benefit, and how should these findings shape future ATTR-CM treatment strategies?



























